These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10759023)

  • 1. Hyperhomocysteinaemia as a cardiovascular risk factor: an update.
    van der Griend R; Biesma DH; Banga JD
    Neth J Med; 2000 Mar; 56(3):119-30. PubMed ID: 10759023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmethionine-load homocysteine determination for the diagnosis hyperhomocysteinaemia and efficacy of homocysteine lowering treatment regimens.
    van der Griend R; Biesma DH; Banga JD
    Vasc Med; 2002 Feb; 7(1):29-33. PubMed ID: 12083731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease.
    Sunder-Plassmann G; Winkelmayer WC; Födinger M
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2637-51. PubMed ID: 11060826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M;
    Clin Chem Lab Med; 2003 Nov; 41(11):1392-403. PubMed ID: 14656016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study.
    de Jong SC; Stehouwer CD; van den Berg M; Geurts TW; Bouter LM; Rauwerda JA
    J Intern Med; 1999 Jul; 246(1):87-96. PubMed ID: 10447230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine-lowering treatment: an overview.
    van Guldener C; Stehouwer CD
    Expert Opin Pharmacother; 2001 Sep; 2(9):1449-60. PubMed ID: 11585023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk factors for cardiovascular diseases: what is the role for homocysteine?].
    Bendini MG; Lanza GA; Mazza A; Giordano A; Leggio M; Menichini G; De Cristofaro R; Moriconi E; Cozzari L; Farina SM; Giordano G
    G Ital Cardiol (Rome); 2007 Mar; 8(3):148-60. PubMed ID: 17461357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine and arterial thrombosis: Challenge and opportunity.
    Di Minno MN; Tremoli E; Coppola A; Lupoli R; Di Minno G
    Thromb Haemost; 2010 May; 103(5):942-61. PubMed ID: 20352150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Homocysteine levels: measure or not?].
    Smulders YM; den Heijer M; Blom HJ
    Ned Tijdschr Geneeskd; 2013; 157(44):A6265. PubMed ID: 24168846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperhomocysteinemia: an additional cardiovascular risk factor.
    Fanapour PC; Yug B; Kochar MS
    WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-vitamins, homocysteine metabolism and CVD.
    Strain JJ; Dowey L; Ward M; Pentieva K; McNulty H
    Proc Nutr Soc; 2004 Nov; 63(4):597-603. PubMed ID: 15831132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia.
    Spoelstra-de MA; Brouwer CB; Terheggen F; Bollen JM; Stehouwer CD; Smulders YM
    Neth J Med; 2004; 62(7):246-53. PubMed ID: 15554600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
    Clarke R; Armitage J
    Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism.
    Dragani A; Falco A; Santilli F; Basili S; Rolandi G; Cerasa L; Lattanzio S; Ciabattoni G; Patrono C; Davì G
    Thromb Haemost; 2012 Sep; 108(3):533-42. PubMed ID: 22782530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel risk factors for vascular disease: the homocysteine hypothesis of cardiovascular disease.
    Wilcken DE
    J Cardiovasc Risk; 1998 Aug; 5(4):217-21. PubMed ID: 9919468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia.
    O'Donnell J; Perry DJ
    Expert Opin Pharmacother; 2002 Nov; 3(11):1591-8. PubMed ID: 12437493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutritional aspects and possible pathological mechanisms of hyperhomocysteinaemia: an independent risk factor for vascular disease.
    McKinley MC
    Proc Nutr Soc; 2000 May; 59(2):221-37. PubMed ID: 10946791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives.
    van der Griend R; Haas FJ; Biesma DH; Duran M; Meuwissen OJ; Banga JD
    Atherosclerosis; 1999 Mar; 143(1):177-83. PubMed ID: 10208493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of hyperhomocysteinaemia in cardiovascular, haematology and nephrology patients: contribution of folate deficiency.
    Donnelly JG; Isotalo PA
    Ann Clin Biochem; 2000 May; 37 ( Pt 3)():304-12. PubMed ID: 10817243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.